O	0	2	An
O	3	7	open
O	7	8	-
O	8	13	label
O	13	14	,
O	15	25	randomized
O	26	31	phase
O	32	34	II
O	35	40	study
O	41	43	of
B-intervention	44	56	adecatumumab
O	56	57	,
O	58	59	a
O	60	65	fully
O	66	71	human
O	72	76	anti
O	76	77	-
O	77	82	EpCAM
O	83	91	antibody
O	91	92	,
O	93	95	as
O	96	107	monotherapy
O	108	110	in
B-eligibility	111	119	patients
I-eligibility	120	124	with
I-eligibility	125	135	metastatic
I-eligibility	136	142	breast
I-eligibility	143	149	cancer
O	149	150	.

O	151	155	High
O	155	156	-
O	156	161	level
O	162	172	expression
O	173	175	of
O	176	186	epithelial
O	187	191	cell
O	192	200	adhesion
O	201	209	molecule
O	210	211	(
O	211	216	EpCAM
O	216	217	)
O	218	220	is
O	221	231	associated
O	232	236	with
O	237	248	unfavorable
O	249	258	prognosis
O	259	261	in
O	262	268	breast
O	269	275	cancer
O	275	276	.

O	277	281	This
O	282	287	study
O	288	291	was
O	292	300	designed
O	301	303	to
O	304	315	investigate
O	316	319	two
O	320	325	doses
O	326	328	of
O	329	332	the
O	333	338	fully
O	339	344	human
O	345	349	IgG1
O	350	354	anti
O	354	355	-
O	355	360	EpCAM
O	361	369	antibody
O	370	382	adecatumumab
O	383	384	(
O	384	389	MT201
O	389	390	)
O	391	393	in
O	394	402	patients
O	403	407	with
O	408	418	metastatic
O	419	425	breast
O	426	432	cancer
O	433	434	(
O	434	437	MBC
O	437	438	)
O	438	439	.

O	440	441	A
O	442	447	total
O	448	450	of
B-total-participants	451	454	109
O	455	463	patients
O	464	468	were
O	469	479	stratified
O	480	484	into
O	485	489	high
O	489	490	-
O	491	494	and
O	495	498	low
O	498	499	-
O	499	504	level
O	505	510	EpCAM
O	511	521	expression
O	522	524	by
O	525	544	immunohistochemical
O	545	553	staining
O	554	556	of
O	557	564	primary
O	565	571	tumors
O	572	575	and
O	576	588	subsequently
O	589	597	randomly
O	598	606	assigned
O	607	609	to
O	610	617	receive
O	618	629	monotherapy
O	630	634	with
O	635	641	either
O	642	646	high
O	646	647	-
O	648	649	(
O	649	650	6
O	651	653	mg
O	653	654	/
O	654	656	kg
O	657	662	every
O	663	666	two
O	667	672	weeks
O	673	674	(
O	674	677	q2w
O	677	678	)
O	678	679	)
O	680	682	or
O	683	686	low
O	686	687	-
O	687	691	dose
O	692	704	adecatumumab
O	705	706	(
O	706	707	2
O	708	710	mg
O	710	711	/
O	711	713	kg
O	713	714	/
O	715	718	q2w
O	718	719	)
O	720	725	until
O	726	733	disease
O	734	745	progression
O	745	746	.

O	747	749	No
O	750	758	complete
O	759	761	or
O	762	769	partial
O	770	775	tumor
O	776	785	responses
O	786	791	could
O	792	794	be
O	795	804	confirmed
O	805	807	by
O	808	815	central
O	816	822	RECIST
O	823	833	assessment
O	833	834	.

O	835	838	The
O	839	850	probability
O	851	854	for
B-outcome	855	860	tumor
I-outcome	861	872	progression
O	873	876	was
O	877	890	significantly
O	891	896	lower
O	897	899	in
O	900	908	patients
O	909	918	receiving
O	919	923	high
O	923	924	-
O	924	928	dose
O	929	941	adecatumumab
O	942	945	and
O	946	956	expressing
O	957	961	high
O	962	968	levels
O	969	971	of
O	972	977	EpCAM
O	978	979	(
O	979	985	hazard
O	986	991	ratio
O	992	993	0
O	993	994	.
O	994	996	43
O	996	997	;
O	998	999	P
O	1000	1001	=
O	1002	1003	0
O	1003	1004	.
O	1004	1008	0057
O	1009	1015	versus
O	1016	1019	low
O	1020	1024	dose
O	1025	1028	and
O	1029	1032	low
O	1033	1038	EpCAM
O	1038	1039	)
O	1039	1040	.

B-iv-bin-abs	1041	1046	Three
O	1047	1049	of
B-intervention-participants	1050	1052	18
O	1053	1061	patients
O	1062	1066	with
O	1067	1074	highest
O	1075	1080	EpCAM
O	1081	1091	expression
O	1092	1099	treated
O	1100	1104	with
O	1105	1117	adecatumumab
O	1118	1127	developed
B-outcome	1128	1131	new
I-outcome	1132	1142	metastases
I-outcome	1143	1145	up
I-outcome	1146	1148	to
I-outcome	1149	1153	week
I-outcome	1154	1155	6
O	1155	1156	,
O	1157	1165	compared
O	1166	1170	with
B-cv-bin-abs	1171	1173	14
O	1174	1176	of
B-control-participants	1177	1179	29
O	1180	1188	patients
O	1189	1193	with
O	1194	1197	low
O	1198	1203	EpCAM
O	1203	1204	.

O	1205	1209	Most
O	1210	1218	frequent
O	1219	1228	treatment
O	1228	1229	-
O	1229	1236	related
B-outcome	1237	1244	adverse
I-outcome	1245	1251	events
O	1252	1253	(
O	1253	1257	high
O	1258	1262	dose
O	1262	1263	/
O	1263	1266	low
O	1267	1271	dose
O	1271	1272	)
O	1273	1277	were
B-outcome	1278	1284	chills
O	1285	1286	(
B-iv-bin-percent	1286	1288	59
I-iv-bin-percent	1288	1289	%
O	1289	1290	/
B-cv-bin-percent	1290	1292	20
I-cv-bin-percent	1292	1293	%
O	1293	1294	)
O	1294	1295	,
B-outcome	1296	1302	nausea
O	1303	1304	(
B-iv-bin-percent	1304	1306	55
I-iv-bin-percent	1306	1307	%
O	1307	1308	/
B-cv-bin-percent	1308	1310	18
I-cv-bin-percent	1310	1311	%
O	1311	1312	)
O	1312	1313	,
B-outcome	1314	1321	fatigue
O	1322	1323	(
B-iv-bin-percent	1323	1325	39
I-iv-bin-percent	1325	1326	%
O	1326	1327	/
B-cv-bin-percent	1327	1329	23
I-cv-bin-percent	1329	1330	%
O	1330	1331	)
O	1332	1335	and
B-outcome	1336	1344	diarrhea
O	1345	1346	(
B-iv-bin-percent	1346	1348	43
I-iv-bin-percent	1348	1349	%
O	1349	1350	/
B-cv-bin-percent	1350	1351	7
I-cv-bin-percent	1351	1352	%
O	1352	1353	)
O	1353	1354	.

O	1355	1361	Single
O	1361	1362	-
O	1362	1367	agent
O	1368	1380	adecatumumab
O	1381	1386	shows
O	1387	1391	dose
O	1391	1392	-
O	1393	1396	and
O	1397	1403	target
O	1403	1404	-
O	1404	1413	dependent
O	1414	1422	clinical
O	1423	1431	activity
O	1432	1434	in
O	1435	1440	EpCAM
O	1440	1441	-
O	1441	1449	positive
O	1450	1453	MBC
O	1453	1454	,
O	1455	1461	albeit
O	1462	1464	no
O	1465	1474	objective
O	1475	1480	tumor
O	1481	1491	regression
O	1491	1492	.

O	1493	1500	Further
O	1501	1514	investigation
O	1515	1517	of
O	1518	1530	adecatumumab
O	1531	1533	in
O	1534	1542	patients
O	1543	1547	with
O	1548	1553	EpCAM
O	1553	1554	-
O	1554	1568	overexpressing
O	1569	1575	tumors
O	1576	1579	and
O	1580	1585	lower
O	1586	1591	tumor
O	1592	1598	burden
O	1599	1601	is
O	1602	1611	warranted
O	1611	1612	.
